Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M896Revenue (TTM) $M908Net Margin (%)-19.9Altman Z-Score0.9
Enterprise Value $M1,494EPS (TTM) $-2.5Operating Margin %-22.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.0Pre-tax Margin (%)-32.2Higher ROA y-yN
Price/Book1.010-y EBITDA Growth Rate %--Quick Ratio1.6Cash flow > EarningsY
Price/Sales1.05-y EBITDA Growth Rate %-13.4Current Ratio2.1Lower Leverage y-yN
Price/Free Cash Flow9.8y-y EBITDA Growth Rate %-239.5ROA % (ttm)-9.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-17.6Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M73.9ROIC % (ttm)-10.0Gross Margin Increase y-yN

Gurus Latest Trades with IPXL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
IPXLNWQ Managers 2016-09-30 Add0.31%$21.72 - $31.62
($26.88)
$ 12.05-55%Add 473.37%1,068,795
IPXLJoel Greenblatt 2016-09-30 Sold Out -0.25%$21.72 - $31.62
($26.88)
$ 12.05-55%Sold Out0
IPXLJoel Greenblatt 2016-06-30 Add0.09%$28.01 - $36.4
($32.59)
$ 12.05-63%Add 53.33%733,848
IPXLNWQ Managers 2016-06-30 Reduce$28.01 - $36.4
($32.59)
$ 12.05-63%Reduce -2.23%186,406
IPXLJoel Greenblatt 2016-03-31 Add0.16%$30.73 - $42.76
($35.27)
$ 12.05-66%Add 2317.15%478,620
IPXLNWQ Managers 2016-03-31 Reduce-0.01%$30.73 - $42.76
($35.27)
$ 12.05-66%Reduce -3.89%190,660
IPXLNWQ Managers 2015-12-31 Reduce-0.21%$34.53 - $44.76
($40.13)
$ 12.05-70%Reduce -66.75%198,378
IPXLJoel Greenblatt 2015-12-31 Buy 0.01%$34.53 - $44.76
($40.13)
$ 12.05-70%New holding19,801
IPXLNWQ Managers 2015-09-30 Reduce-0.07%$33.27 - $50.42
($45.1)
$ 12.05-73%Reduce -16.00%596,619
IPXLNWQ Managers 2015-06-30 Reduce-0.13%$44.44 - $51.31
($47.45)
$ 12.05-75%Reduce -24.12%710,302
IPXLGeorge Soros 2015-06-30 Sold Out -0.03%$44.44 - $51.31
($47.45)
$ 12.05-75%Sold Out0
IPXLGeorge Soros 2015-03-31 Buy 0.03%$30.2 - $47.3
($39.79)
$ 12.05-70%New holding61,206
IPXLJoel Greenblatt 2015-03-31 Sold Out -0.02%$30.2 - $47.3
($39.79)
$ 12.05-70%Sold Out0
IPXLNWQ Managers 2015-03-31 Add0.02%$30.2 - $47.3
($39.79)
$ 12.05-70%Add 3.32%936,127
IPXLMario Gabelli 2015-03-31 Sold Out -0.0011%$30.2 - $47.3
($39.79)
$ 12.05-70%Sold Out0
IPXLNWQ Managers 2014-12-31 Reduce-0.1%$23.63 - $32.75
($29.3)
$ 12.05-59%Reduce -30.25%906,043
IPXLJoel Greenblatt 2014-12-31 Add0.01%$23.63 - $32.75
($29.4)
$ 12.05-59%Add 136.17%79,609
IPXLMario Gabelli 2014-12-31 Buy $23.63 - $32.75
($29.3)
$ 12.05-59%New holding6,775
IPXLNWQ Managers 2014-09-30 Add0.08%$22.77 - $30.68
($25.55)
$ 12.05-53%Add 31.90%1,298,995
IPXLJoel Greenblatt 2014-09-30 Buy 0.01%$22.77 - $30.68
($25.55)
$ 12.05-53%New holding33,709
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

IPXL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


IPXL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BENET LESLIE ZDirector 2016-08-15Sell10,092$22.81-47.17view
SCHLOSSBERG MARK ASVP and General Counsel 2015-09-11Sell7,457$43.3-72.17view
NESTOR MICHAELPresident, Impax Pharm. 2015-09-10Sell5,000$43.56-72.34view
FLEMING NIGELDirector 2015-08-31Sell29,166$41.02-70.62view
MARKBREITER MICHAELDirector 2015-08-31Sell28,000$41.7-71.1view
BENET LESLIE ZDirector 2015-08-31Sell20,000$40.92-70.55view
SCHLOSSBERG MARK ASVP and General Counsel 2015-08-27Sell4,649$43.41-72.24view
TERRERI PETER RDirector 2015-08-27Sell4,833$43.93-72.57view
MARKBREITER MICHAELDirector 2015-08-26Sell19,399$42.24-71.47view
HSU LARRYDirector 2014-06-06Sell100,000$28.38-57.54view

Quarterly/Annual Reports about IPXL:

News about IPXL:

Articles On GuruFocus.com
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 
Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 
Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 
Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' 3rd-Quarter Activity Nov 27 2015 
Kyle Bass Goes Fishing for These 3 New Holdings Nov 26 2015 
Alan Fournier's Highest Performing Stocks Jul 15 2015 
Alan Fournier's Most Heavily Weighted Trades In Q1 2015 May 28 2015 

More From Other Websites
Is Impax a Great Stock for Value Investors? Jan 19 2017
CVS takes on Mylan’s EpiPen with much cheaper version of an alternative Jan 15 2017
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlighted as Zacks... Jan 13 2017
Biotech Premarket Movers: SGMO, IPXL, PTLA Jan 13 2017
Cheaper Epinephrine: Spend Way Less With This EpiPen Alternative Jan 12 2017
UPDATE 1-CVS slashes price of Impax's EpiPen rival Jan 12 2017
CVS slashes price of Impax's emergency allergy shot Jan 12 2017
Mylan Crushed by Trump, Cigna and CVS -- All In Two Days Jan 12 2017
[$$] Cigna Drops EpiPen Coverage for Generic Jan 12 2017
CVS Debuts Cheap EpiPen Alternative Jan 12 2017
CVS Is the Latest to Rock Mylan's EpiPen Empire Jan 12 2017
Cigna Defends Abandoning EpiPen Coverage Jan 12 2017
IMPAX LABORATORIES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 11 2017
Biotech Premarket Movers: IPXL, SGMO, ARLZ Jan 11 2017
DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Impax Laboratories,... Jan 09 2017
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Jan 09 2017
Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit Jan 09 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of... Jan 07 2017
IMPAX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and... Jan 06 2017
Bernstein Liebhard LLP Announces That A Suit Has Been Filed Against Impax Laboratories, Inc. Jan 06 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)